These results indicate that in patients with intermediate to high-risk prostate cancer, PSMA-PET used in conjunction with MRI is more sensitive than mpMRI when staging SVI and the spread of cancer beyond the prostate gland. The gene discussed is FOLH1; the disease is cancer.